Edap Tms (NASDAQ:EDAP) versus Medios (OTCMKTS:MEDOF) Head-To-Head Contrast

Edap Tms (NASDAQ:EDAP) and Medios (OTCMKTS:MEDOF) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Institutional and Insider Ownership

62.7% of Edap Tms shares are owned by institutional investors. 0.2% of Edap Tms shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Edap Tms and Medios’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edap Tms	$65.42 million	4.14	-$22.92 million	($0.63)	-11.59
Medios	N/A	N/A	N/A	N/A	N/A

Medios has lower revenue, but higher earnings than Edap Tms.

Profitability

This table compares Edap Tms and Medios’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edap Tms	-35.03%	-34.33%	-22.28%
Medios	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Edap Tms and Medios, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edap Tms	0	0	2	0	3.00
Medios	0	0	0	0	N/A

Edap Tms presently has a consensus target price of $14.67, suggesting a potential upside of 100.91%. Given Edap Tms’ higher probable upside, research analysts plainly believe Edap Tms is more favorable than Medios.

Summary

Edap Tms beats Medios on 5 of the 8 factors compared between the two stocks.

About Edap Tms

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves hospitals, urology clinics, and research institutions. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France.

About Medios

Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment includes cytostatic infusion preparations, antibody therapies, virostatic and antibiotic medications, parenteral nutrition solutions, and investigational medicinal products. Medios AG was founded in 2016 and is headquartered in Berlin, Germany.